Immix to Initiate Phase 1/2a Trial of IMX-110 in Ovarian, Other Solid Tumors

Immix to Initiate Phase 1/2a Trial of IMX-110 in Ovarian, Other Solid Tumors
A Phase 1/2a trial of Immix Biopharma’s IMX-110, a combination treatment targeting advanced solid tumors, including ovarian cancer, has received the necessary ethics board approval to begin. The trial (NCT03382340) will explore the safety, tolerability, and pharmacokinetics (how the body metabolizes, distributes, and excretes a medicine) of IMX-110 in patients with a variety of advanced solid tumors. IMX-110 has already shown effectiveness in fighting glioblastoma, multiple myeloma, and pancreatic, colorectal, triple negative breast, and ovarian cancers in animal models. According to Immix, IMX-100 caused tumors to shrink in animals with pancreatic cancer. It also boosted the animals’ immune response to tumors by increasing the entry of tumor-killing T-cells into tumors. White blood cells that diminish the immune response and tumor endothelial cells – cells that line the blood vessels in tumo
Subscribe or to access all post and page content.